Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

41141 - 41150 of 63288 results found

First sequenced cases of Omicron BA.2 sublineage in Ecuador

Date
Wednesday, July 05, 2023 - 4:00 AM
Description
The largest wave of infection with SARS-CoV-2 virus in Ecuador was observed in mid-December 2021 and early January 2022, driven by B.1.1.529/BA (Omicron) variant. During the second half of March, an increase in the number of daily cases was observed

Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMP...

Date
Wednesday, July 05, 2023 - 4:00 AM
Description
CONCLUSION: A booster dose of VLA2001 was safe and well tolerated after primary immunization with VLA2001 and ChAdOx1-S. The tolerability of a booster dose of VLA2001 was similar to the favourable profile observed after the first and second priming

Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMP...

Date
Wednesday, July 05, 2023 - 4:00 AM
Description
CONCLUSION: A booster dose of VLA2001 was safe and well tolerated after primary immunization with VLA2001 and ChAdOx1-S. The tolerability of a booster dose of VLA2001 was similar to the favourable profile observed after the first and second priming

Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naïve individuals

Date
Wednesday, July 05, 2023 - 4:00 AM
Description
Antibodies triggering Fc-mediated NK cell activity may contribute to protection against disease caused by SARS-CoV-2 infection in humans. However, how these Fc-mediated humoral responses compare between individuals displaying hybrid immunity (Vac-ex)